# Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

> **NCT01714089** · PHASE2 · WITHDRAWN · sponsor: **Revalesio Corporation**

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** RNS60 125 ml
- **DRUG:** RNS60 250 ml
- **DRUG:** Interferon beta 1a

## Key facts

- **NCT ID:** NCT01714089
- **Lead sponsor:** Revalesio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714089, "Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01714089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*